Equity · Healthcare
GILD
NASDAQGilead Sciences (GILD)
The line runs 133.07 USD on 10 August through 166.87 USD on 6 November, on a scale from 120 to 180. Days the market did not trade hold the previous close, flat.
- Market cap
- 207.0B USD
- Revenue, year to Dec 2025
- 29.4B USD
- EPS, diluted, year to Dec 2025
- 6.78 USD
- 52-week range
- 113 USD – 174.45 USD
- Avg volume
- 299.7K
- Mentions, 30 days
- 7
- Net sentiment
- +0.22
as of Nov 6, 2026
Have Gilead Sciences (GILD) insiders bought or sold shares recently?
In the 90 days to 9 Nov 2026, Gilead Sciences insiders reported 14 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 27 Feb 2026, show no open-market purchase.
Form 4, 90 days to 9 Nov 2026, newest reported trade 5 Nov 2026
Buys 0Sells 14Net sold $38.95MOther filings 20
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 05 Nov 2026 | O'Day Daniel PatrickChairman & CEO | Sell | 9,810 | 1.7M USD |
| 04 Nov 2026 | O'Day Daniel PatrickChairman & CEO | Sell | 102,619 | 18.0M USD |
| 02 Nov 2026 | O'Day Daniel PatrickChairman & CEO | Sell | 15,000 | 2.5M USD |
| 30 Oct 2026 | O'Day Daniel PatrickChairman & CEO | Sell | 15,881 | 2.8M USD |
| 15 Oct 2026 | Dickinson Andrew DChief Financial Officer | Sell | 3,000 | 469K USD |
| 15 Oct 2026 | Mercier JohannaChief Comm & Corp Aff Officer | Sell | 3,000 | 469K USD |
| 01 Oct 2026 | O'Day Daniel PatrickChairman & CEO | Sell | 15,000 | 2.2M USD |
| 15 Sep 2026 | Dickinson Andrew DChief Financial Officer | Sell | 3,000 | 436K USD |
| 15 Sep 2026 | Mercier JohannaChief Comm & Corp Aff Officer | Sell | 3,000 | 433K USD |
| 01 Sep 2026 | O'Day Daniel PatrickChairman & CEO | Sell | 15,000 | 2.2M USD |
| 26 Aug 2026 | WELTERS ANTHONYDirector | Sell | 18,000 | 2.7M USD |
| 20 Aug 2026 | Bluestone JeffreyDirector | Sell | 5,000 | 725K USD |
| Sold | 14 open-market sales | 239,310 | $38.95M |
Showing the 12 most recent of 14 open-market trades in this window. The figures above count all of them.
20 other filings in the window: grants, exercises, tax withholding and transfers, not trades
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 05 Nov 2026 | O'Day Daniel PatrickChairman & CEO | Option exercise | 9,810 | 710K USD |
| 04 Nov 2026 | O'Day Daniel PatrickChairman & CEO | Option exercise | 102,619 | 7.4M USD |
| 30 Oct 2026 | O'Day Daniel PatrickChairman & CEO | Option exercise | 15,881 | 1.1M USD |
| 22 Sep 2026 | Burkhart ErinSVP, Controllership | Option exercise | 2,223 | |
| 22 Sep 2026 | Burkhart ErinSVP, Controllership | Tax withheld | 768 | 117K USD |
| 10 Sep 2026 | Berger DietmarChief Medical Officer | Option exercise | 533 | |
| 10 Sep 2026 | Berger DietmarChief Medical Officer | Tax withheld | 263 | 38K USD |
| 10 Sep 2026 | Cain Wettan Keeley MEVP Gen Counsel, Legal & Comp | Option exercise | 590 | |
| 10 Sep 2026 | Cain Wettan Keeley MEVP Gen Counsel, Legal & Comp | Tax withheld | 285 | 41K USD |
| 10 Sep 2026 | Dickinson Andrew DChief Financial Officer | Option exercise | 2,797 | |
| 10 Sep 2026 | Dickinson Andrew DChief Financial Officer | Tax withheld | 1,347 | 195K USD |
| 10 Sep 2026 | O'Day Daniel PatrickChairman & CEO | Option exercise | 8,780 |
Showing the 12 most recent of 20 compensation filings in this window. The figures above count all of them.
Which funds hold Gilead Sciences (GILD)?
1 of the 45 institutional funds we track reported a Gilead Sciences position for the quarter ended 30 Sep 2026 — a combined 45.6M USD; the latest of those filings landed 06 Nov 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Fisher Asset Management | Added | 305,850 | 45.6M USD | +1,516.0% |
Have members of Congress traded Gilead Sciences (GILD)?
The most recent congressional trade disclosed in Gilead Sciences is a purchase by Jared Moskowitz (house, FL), dated 06 May 2026.
STOCK Act disclosures
| Traded | Member | Type | Amount | Filed after |
|---|---|---|---|---|
| 06 May 2026 | Jared Moskowitzhouse · Democrat–FL | Purchase | 1K USD–15K USD | 44 days |
| 23 Sep 2025 | Val T. Hoylehouse · Democrat–OR | Sale | 1K USD–15K USD | 17 days |
| 14 May 2025 | Josh Gottheimerhouse · Democrat–NJ | Sale | 1K USD–15K USD | 28 days |
| 10 Mar 2025 | Carol D. Millerhouse · Republican–WV | Purchase | 1K USD–15K USD | 32 days |
| 07 Mar 2025 | Josh Gottheimerhouse · Democrat–NJ | Purchase | 1K USD–15K USD | 34 days |
| 29 Oct 2024 | Val T. Hoylehouse · Democrat–OR | Purchase | 1K USD–15K USD | 318 days |
| 24 Oct 2023 | Greg Stantonhouse · Democrat–AZ | Sale | 1K USD–15K USD | 16 days |
| 26 Sep 2023 | Greg Stantonhouse · Democrat–AZ | Purchase | 1K USD–15K USD | 44 days |
What has been filed or recorded for Gilead Sciences (GILD)?
The filings we hold for Gilead Sciences, newest first: 2 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 09 Oct 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 09 Oct 2026 | Fails to deliver | Shares failed to deliver | 81,355 shares | 12.0M USD notional · 0.007% of shares out |
| 08 Oct 2026 | Fails to deliver | Shares failed to deliver | 360 shares | 53K USD notional · <0.001% of shares out |
| 30 Sep 2026 | Quarterly earnings | Q3 2026 reported | EPS 1.94 USD | |
| 30 Sep 2026 | Financials | Total assets | 51.4B USD | at period end |
| 30 Sep 2026 | Financials | Total equity | 13.0B USD | at period end |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS −8.45 USD | |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS 1.61 USD | |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS 6.78 USD | |
| 31 Dec 2025 | Financials | Revenue | 29.4B USD | fiscal year |
| 31 Dec 2025 | Financials | Net income | 8.5B USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | 6.78 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS 2.43 USD | |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS 1.56 USD | |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS 1.04 USD | |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS 0.38 USD |
What is Reddit saying about Gilead Sciences (GILD)?
Reddit mentioned GILD 7 times in the 30 days to 8 November 2026, across 2 of the communities we track. All of them were scored for sentiment: 100% read bullish, 0% bearish and 0% neither. Reddit data updated 8 November 2026.
30-day window, Method
Mentions, 30 days 7Bullish 100%Bearish 0%Communities 2Against the market +46 points
How do Reddit mentions of Gilead Sciences (GILD) compare with its price?
Share ↗
Where Gilead Sciences (GILD) is discussed
30 days
| Community | Share | Mentions | Net sentiment |
|---|---|---|---|
| r/wallstreetbets | 86% | 6 | +0.14 |
| r/stocks | 14% | 1 | +0.69 |
Gilead Sciences (GILD): frequently asked questions
What did Gilead Sciences shares close at?
Gilead Sciences closed at 166.87 USD on 6 Nov 2026, down 0.45% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is Gilead Sciences’ market cap?
Gilead Sciences is worth 207.0B USD by market value as of 6 Nov 2026, which is the share price times the shares on issue from its SEC filings.
What is Gilead Sciences’ revenue?
Gilead Sciences reported revenue of 29.4B USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings
Have Gilead Sciences insiders bought or sold shares recently?
In the 90 days to 9 Nov 2026, Gilead Sciences insiders reported 14 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 27 Feb 2026, show no open-market purchase. A further 20 filings were grants, awards, gifts or exercises rather than open-market trades. See Insiders
Which funds own Gilead Sciences?
1 of the 45 funds we track reported a Gilead Sciences position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported position was Fisher Asset Management. See Funds
Have members of Congress traded Gilead Sciences?
Yes. 14 trades in Gilead Sciences appear in the congressional disclosures we hold; the latest is a purchase by Jared Moskowitz (House, FL) dated 6 May 2026, filed 19 Jun 2026. Amounts are disclosed as ranges, and a filing can follow the trade by up to 45 days. See Congress
When did Gilead Sciences last report earnings?
Gilead Sciences last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of 1.94 USD; no next date is announced in SEC filings yet. See Filings
What is Reddit saying about Gilead Sciences?
Gilead Sciences was mentioned 0 times in the last 7 days across the finance subreddits we track, and 7 times over the trailing 30 days. Of the 7 mentions scored for sentiment, 100% read bullish and 0% bearish. That is a social signal, not investment advice. See Reddit
Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- RedditReddit ingest across the tracked finance subreddits
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- House disclosuresU.S. House of Representatives financial disclosures
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings